Abpro Holdings Employees

As of December 31, 2025, Abpro Holdings had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees decreased by 12 or -80.00% compared to the previous year.

Employees

Change (1Y)

-12

Growth (1Y)

-80.00%

Revenue / Employee

n/a

Profits / Employee

-$1,446,000

Market Cap

1.05M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)	Full-Time	Part-Time
Dec 31, 2025	3	-12	-80.00%	1	2
Dec 31, 2024	15	-	-	6	9
Sep 30, 2024	16	-	-	15	1
Jun 30, 2024	16	-	-	15	1

Related Stocks

Company Name	Employees
LakeShore Biopharma	573
Adaptimmune Therapeutics	506
Evofem Biosciences	29
Lyra Therapeutics	27
Windtree Therapeutics	14
Eloxx Pharmaceuticals	10

Employee Rankings

Abpro Holdings News

3 months ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
4 months ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
5 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
5 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
6 months ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
6 months ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
1 year ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
1 year ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire

More News